Publication:
The efficacy in melasma treatment using a 1410 nm fractional photothermolysis laser

dc.contributor.authorR. Wanitphakdeedechaen_US
dc.contributor.authorN. Keoprasomen_US
dc.contributor.authorS. Eimpunthen_US
dc.contributor.authorW. Manuskiattien_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-11-09T02:39:10Z
dc.date.available2018-11-09T02:39:10Z
dc.date.issued2014-03-01en_US
dc.description.abstractBackground Melasma treatment modalities including topical and procedural therapy have been employed with variable results and high recurrence rate. Objective To quantitatively assess improvement in melasma and side effects after 1410 nm fractional photothermolysis laser treatments and to determine efficacy at 1-, 2- and 3-month follow-up after treatment. Methods Thirty volunteers with melasma were treated with 1410 nm fractional photothermolysis for four passes on full face and additional four passes on melasma area. They were randomly treated on one side of their face with 20 mJ at 5% coverage and the other side of their face with 20 mJ at 20% coverage. All subjects were treated monthly for five times. Melanin index, Visual analogue scale and Melasma Area and Severity Index score were measured at baseline and 1-, 2- and 3-month follow-up after complete treatment protocol. Results There was statistically significant improvement of Melanin index at 2- and 3-month follow-up visits, but not at 1-month follow-up visit. Visual analogue scale and Melasma Area and Severity Index score improved significantly on both sides at 1-, 2- and 3-month follow-ups. The overall patients' satisfaction was significantly higher on the side treated with 20 mJ, 5% coverage. Adverse reactions included erythema, dryness and post-inflammatory hyperpigmentation on melasma area. Those side effects were significantly more intense on the side treated with 20 mJ, 20% coverage. Conclusions 1410 nm fractional photothermolysis laser treatment is a safe and temporary effective procedure for melasma; however, long-term follow-up is still needed. Only 5% coverage should be used to minimize risks of adverse effects. © 2013 European Academy of Dermatology and Venereology.en_US
dc.identifier.citationJournal of the European Academy of Dermatology and Venereology. Vol.28, No.3 (2014), 293-297en_US
dc.identifier.doi10.1111/jdv.12100en_US
dc.identifier.issn14683083en_US
dc.identifier.issn09269959en_US
dc.identifier.other2-s2.0-84894451581en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/34272
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84894451581&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleThe efficacy in melasma treatment using a 1410 nm fractional photothermolysis laseren_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84894451581&origin=inwarden_US

Files

Collections